SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Mergers and acquisitions

Mergers and acquisitions

The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.

Hikma buys B-I generics subsidiary, strengthens position in US market

28-Jul-2015 - Hikma says its $2.65bn acquisition of Roxane Laboratories will make it the sixth largest firm in the US generics space.

Update

Teva to buy Allergan's generics biz for $40.5bn

27-Jul-2015 - Teva has struck a deal to buy Allergan’s generics business a week after its persistent attempts to acquire Mylan fell through.

Summit up as Celgene steps in to buy Merck & Co. campus

21-Jul-2015 - Celgene will take over a Merck & Co. facility in Summit, New Jersey which had been earmarked for closure.

News in brief

Torrent acquires Indian dermatological drugmaker Zyg

20-Jul-2015 - Torrent Pharma has added two facilities to its network through the acqusition of Zyg Pharma from the Encore Group.

Celgene boosting immune-inflammatory presence with $7.2bn Receptos deal

16-Jul-2015 - Celgene has shelled out $7.2bn (€6.6bn) to acquire Receptos which is developing an oral lymphocyte trafficking agent for multiple sclerosis and inflammatory bowel disorder.

'Outperform' Perrigo better off without Mylan, says analyst report

30-Jun-2015 - The proposed Perrigo merger with Mylan would be of no benefit to either firm in the “highly competitive” OTC sector, according to financial analysts BMO.

‘Record-breaking’ 2015 will see surge in pharma acquisitions

25-Jun-2015 - Demand for CNS assets will help break records for pharma M&As in 2015, Neel Patel, VP of inVentiv Health consultancy Campbell Alliance, tells in-Pharmatechnologist.com. 

Dealing with activist shareholders: Allergan CEO shares advice at BIO

18-Jun-2015 - Ex-Allergan CEO David Pyott has spoken of his “total war” battling Valeant’s failed hostile takeover, and given advice to other pharmaceutical companies on how to deal with activist shareholders.

UPDATE - Mylan demands a straightforward answer to whether Teva will make a legally binding exchange offer

Teva to Mylan: We will accomplish our 'strong and serious' takeover proposal

08-Jun-2015 - Teva has refuted accusations of “meddling” with Mylan’s business in the latest chapter of what one analyst says is a far from friendly, if not hostile takeover attempt.

Mylan to Teva: 'Stop meddling in our affairs'

02-Jun-2015 - Teva has been accused of "playing games" with Mylan by acquiring a 1.35% stake in the generics firm weeks after having a $40bn (EUR36bn) takeover bid snubbed....

EC competition concerns will not stop $17bn Sigma-Aldrich deal, says Merck

28-May-2015 - Merck KGaA is confident it will close the $17bn acquisition of Sigma-Aldrich in mid-2015 despite competition concerns from the European Commission (EC).

Endo buys Par, Lupin enters Brazil... it's been a busy week in generics

19-May-2015 - Endo’s $8bn takeover of Par Pharmaceutical is expected to shake-up the generics sector, while Lupin is expanding its South American network – welcome to In-Pharmatechnologist’s M&A round-up.

Hospira approval puts Pfizer on track to close $17bn deal by year's end

18-May-2015 - Pfizer is set to close its $17bn (€15bn) acquisition by the end of the year after receiving the thumbs up from Hospira shareholders.

Siegfried set to buy custom synthesis and API units from BASF for $300m

07-May-2015 - BASF says it remains committed to the pharma industry despite plans to divest its custom synthesis business and around 100 APIs and intermediates to Siegfried Holding.

AMRI riding high on API acquisitions, expects more M&A to come

06-May-2015 - AMRI attributed a robust first quarter to its growing API business and recent acquisitions, and says to expect more M&A activity this year.

Mylan rejects $40bn bid, questions Teva’s credibility

28-Apr-2015 - Mylan has rejected an unsolicited bid by Teva and upped its offer for Perrigo, as the ongoing saga in the generics space continues.

Special from BPI Europe 2015

Eliminating fear culture can save operational costs and jobs, says Pfizer

23-Apr-2015 - Pfizer reduced costs 40% without cutting jobs at a facility in Sweden using an alternative approach to organisational and cultural behaviour, and hopes to do the same at its newly acquired Austrian...

Update

Teva bids $40bn for Mylan in proposed generics megamerger

21-Apr-2015 - A merger with Mylan would “transform the global generics space” says Teva, which has entered a $40bn bid as an alternative to the recently proposed Mylan-Perrigo deal.

Allergan axing a further 577 at Cali HQ, post-Actavis acquisition

21-Apr-2015 - Almost 600 staff at Allergan’s headquarters in Irvine, California, will be laid off in the Botox maker’s latest round of job cuts.

My oh Mylan! $29bn Perrigo deal would create 'unrivalled' manufacturing network

09-Apr-2015 - Mylan has bid $29bn (€27bn) to buy Perrigo in what the firm says will create a company with “unrivalled” manufacturing and supply chain capabilities across OTCs, generics and APIs.

Columbia Labs adds intra-vaginal ring tech and drug delivery pioneers

31-Mar-2015 - Columbia Laboratories has licensed a technology for delivering peptides using an intra-vaginal ring developed by MIT scientist Robert Langer.

No more waiting for the Sun: FTC approves $4bn Ranbaxy acquisition

30-Mar-2015 - Sun Pharmaceutical Industries has completed its $4bn (€3.7bn) acquisition of Ranbaxy after receiving the thumbs up from the US Federal Trade Commission (FTC).

AbbVie buys Pharmacyclics, bags Imbruvica blood cancer blockbuster

05-Mar-2015 - AbbVie is set to buy Californian small-molecule maker Pharmacyclics for $21bn (€19bn), cementing its haematology-oncology business.

Sun Pharma goes after opiates with deal to buy GSK’s Aus business

03-Mar-2015 - Indian giant Sun Pharma has bought GSK’s Australian Opiates business.

FTC requires Novartis to divest two potential cancer drugs to Array as part of GSK deal

24-Feb-2015 - In order to close Novartis’ $16bn purchase of GlaxoSmithKline’s portfolio of cancer treatments , the FTC (Federal Trade Commission) is requiring Novartis to divest all assets related to its potential BRAF and...

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...